SUNNIFORECAST试验中乳头状肾细胞癌亚组:伊匹木单抗联合纳武利尤单抗对比标准治疗
SUNNIFORECAST是一项II期试验,在未治疗晚期非透明细胞肾癌中比较伊匹木单抗联合纳武利尤单抗与标准治疗。经中心病理复核确认的127例乳头状肾细胞癌患者中,联合组12个月总生存率为74.77%,标准治疗组为63.44%(p=0.085),中位总生存分别为24.89个月和18.88个月。探索性分析提示联合治疗可能带来获益,尤其在PD-L1 CPS>1的患者中。
要点
- 中心病理复核使56/173例局部诊断的乳头状肾细胞癌被修正。
- 乳头状亚组中联合组12个月OS率74.77% vs 标准治疗63.44%(p=0.085)。
- CPS>1患者中联合组12个月OS率82.38% vs 标准治疗63.33%。
核心结论
- 探索性分析提示伊匹木单抗联合纳武利尤单抗在乳头状肾细胞癌中可能较标准治疗改善12个月OS率、中位OS和ORR,尤其在CPS>1患者中。
研究设计与样本
- SUNNIFORECAST为前瞻性、研究者发起的II期试验,评估伊匹木单抗联合纳武利尤单抗对比标准治疗用于未治疗晚期非透明细胞肾癌。
- 309例随机患者中127例经中心病理复核确认乳头状组织学,联合组64例、标准治疗组63例(以TKI单药为主)。
- 主要终点为12个月OS率,次要终点包括OS、PFS和ORR,PD-L1表达为探索性评估。
主要发现
- 乳头状亚组12个月OS率联合组74.77% vs 标准治疗组63.44%(p=0.085)。
- 中位OS联合组24.89个月 vs 标准治疗组18.88个月。
- 127例中116例PD-L1可评估,CPS>1随IMDC风险类别升高更常见。
- CPS<1患者12个月OS率联合组75.00% vs 标准治疗组68.36%(p=0.963)。
- CPS>1患者12个月OS率联合组82.38% vs 标准治疗组63.33%。
临床怎么用
- 对乳头状肾细胞癌患者,可考虑伊匹木单抗联合纳武利尤单抗作为一线治疗选择之一,尤其PD-L1 CPS>1者。
- 局部病理诊断的乳头状肾细胞癌建议经中心病理复核确认。
局限性
- 本文为探索性分析,存在若干局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Papillary renal cell cancer (pRCC) represents the largest subgroup within non-clear cell (ncc) RCC. Compared with clear cell RCC (ccRCC), pRCC is considered less sensitive to currently available systemic therapies. Here, we report exploratory results from the pRCC subgroup of the SUNNIFORECAST trial comparing ipilimumab/nivolumab with standard of care (SOC) based on central pathological review. METHODS AND PATIENTS: SUNNIFORECAST was a prospective, investigator-initiated, phase II trial evaluating ipilimumab/nivolumab versus SOC in patients with untreated, advanced nccRCC. The primary endpoint was the 12-month overall survival (OS) rate. Secondary endpoints included OS, progression-free survival (PFS), and overall response rate (ORR). PD-L1 expression was assessed exploratory. RESULTS: Of 309 randomized patients, 127 had confirmed papillary histology, in 56/173 cases the local diagnosis of pRCC required revision. Among the 127 patients with pRCC, 64 received ipilimumab/nivolumab and 63 SOC, predominantly TKI monotherapy. In the pRCC subgroup, the 12-month OS rate was 74.77% in the ipilimumab/nivolumab arm and 63.44% in the SOC arm (p = 0.085). Median OS was 24.89 months with ipilimumab/nivolumab versus 18.88 months with SOC. PD-L1 expression was evaluable in 116 of 127 patients. A CPS > 1 was more frequently observed with increasing IMDC risk category. Among patients with CPS < 1, the 12-month OS rate was 75.00% with ipilimumab/nivolumab and 68.36% with SOC (p = 0.963). In patients with CPS > 1, the 12-month OS rate was 82.38% in the ipilimumab/nivolumab arm and 63.33% in the SOC arm. DISCUSSION: This exploratory analysis has several limitations; however, it suggests that patients with pRCC treated with ipilimumab/nivolumab may derive a benefit in terms of 12-month OS rate, median OS, and ORR compared with SOC, particularly among those with CPS > 1. (Funded by Bristol Myers Squibb grant CA209-499; ClinicalTrials.gov, EUDRACT Number: 2016-000706-12; NCT03075423.).
引用
- Ahrens M, Haanen J, Albiges L, et al. Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. Eur J Cancer. 2026. PMID: 42235464. doi:10.1016/j.ejca.2026.116816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。